These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38820867)

  • 41. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
    Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of voxel S-value methods for personalized voxel-based dosimetry of
    Kim KM; Lee MS; Suh MS; Selvam HSMS; Tan TH; Cheon GJ; Kang KW; Lee JS
    Med Phys; 2022 Mar; 49(3):1888-1901. PubMed ID: 35014699
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T.
    Brosch-Lenz J; Uribe C; Gosewisch A; Kaiser L; Todica A; Ilhan H; Gildehaus FJ; Bartenstein P; Rahmim A; Celler A; Ziegler S; Böning G
    EJNMMI Phys; 2021 Mar; 8(1):26. PubMed ID: 33709253
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The
    Maffey-Steffan J; Scarpa L; Svirydenka A; Nilica B; Mair C; Buxbaum S; Bektic J; von Guggenberg E; Uprimny C; Horninger W; Virgolini I
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):695-712. PubMed ID: 31776632
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors affecting accuracy of S values and determination of time-integrated activity in clinical Lu-177 dosimetry.
    Götz TI; Schmidkonz C; Lang EW; Maier A; Kuwert T; Ritt P
    Ann Nucl Med; 2019 Jul; 33(7):521-531. PubMed ID: 31119607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
    Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
    Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-PSMA Inhibitor Therapy With Metastatic Castration-Resistant Prostate Cancer: One Center Results.
    Özkan A; Uçar B; Seymen H; Yildiz Yarar Y; Falay FO; Demirkol MO
    Clin Nucl Med; 2020 Apr; 45(4):288-291. PubMed ID: 32049721
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of
    Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L
    J Nucl Med; 2023 Feb; 64(2):221-226. PubMed ID: 36008120
    [No Abstract]   [Full Text] [Related]  

  • 49. Radioligand Therapy With
    Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C
    AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089
    [No Abstract]   [Full Text] [Related]  

  • 50. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
    Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies.
    Hou X; Brosch J; Uribe C; Desy A; Böning G; Beauregard JM; Celler A; Rahmim A
    J Nucl Med; 2021 Jul; 62(7):1006-1011. PubMed ID: 33127625
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Personalized dosimetry of
    Carter LM; Ocampo Ramos JC; Kesner AL
    Biomed Phys Eng Express; 2021 Aug; 7(5):. PubMed ID: 34271565
    [No Abstract]   [Full Text] [Related]  

  • 53. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.
    Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Clin Nucl Med; 2018 May; 43(5):323-330. PubMed ID: 29485430
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generation of clinical
    Kayal G; Chauvin M; Vergara-Gil A; Clayton N; Ferrer L; Moalosi T; Knoll P; Struelens L; Bardiès M
    Phys Med; 2021 May; 85():24-31. PubMed ID: 33957577
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Active and passive dosimetry for beta-emitting radiopharmaceutical therapy agents in a custom SPECT/CT compatible phantom.
    Bertinetti A; Garcia T; Palmer B; Rodrigues M; Bradshaw T; Vija AH; Culberson W
    Phys Med Biol; 2024 May; 69(11):. PubMed ID: 38684165
    [No Abstract]   [Full Text] [Related]  

  • 56. Pretherapeutic Comparative Dosimetry of
    Feuerecker B; Chantadisai M; Allmann A; Tauber R; Allmann J; Steinhelfer L; Rauscher I; Wurzer A; Wester HJ; Weber WA; d'Alessandria C; Eiber M
    J Nucl Med; 2022 Jun; 63(6):833-839. PubMed ID: 34531260
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Kristiansson A; Örbom A; Ahlstedt J; Karlsson H; Zedan W; Gram M; Åkerström B; Strand SE; Altai M; Strand J; Vilhelmsson Timmermand O
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33579037
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.
    Fendler WP; Reinhardt S; Ilhan H; Delker A; Böning G; Gildehaus FJ; Stief C; Bartenstein P; Gratzke C; Lehner S; Rominger A
    Oncotarget; 2017 Jan; 8(2):3581-3590. PubMed ID: 27683041
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early response monitoring during [
    Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A;
    Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TestDose: A nuclear medicine software based on Monte Carlo modeling for generating gamma camera acquisitions and dosimetry.
    Garcia MP; Villoing D; McKay E; Ferrer L; Cremonesi M; Botta F; Ferrari M; Bardiès M
    Med Phys; 2015 Dec; 42(12):6885-94. PubMed ID: 26632045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.